COVID-19; Tested Positive on May 24, 2022 after testing negative; This spontaneous case was reported by a patient and describes the occurrence of COVID-19 (Tested Positive on May 24, 2022 after testing negative) and COVID-19 (COVID-19) in a 42-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Previously administered products included for COVID-19 vaccination: Johnson & Johnson (J&J Vaccine and Dose Number: 1 Batch/Lot No: 042A21A Location of injection: Arm Left) on 08-Apr-2021. Past adverse reactions to the above products included No adverse event with Johnson & Johnson. Concurrent medical conditions included Allergy to chemicals (IVP Dye). Concomitant products included ACETAMINOPHEN, CALCIUM CARBONATE (TUMS [CALCIUM CARBONATE]), LISINOPRIL, BECLOMETASONE DIPROPIONATE (QVAR REDIHALER), SALBUTAMOL SULFATE (ALBUTEROL [SALBUTAMOL SULFATE]), CETIRIZINE, ESCITALOPRAM and AZELASTINE for an unknown indication.    On 22-Nov-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 24-May-2022, the patient experienced COVID-19 (Tested Positive on May 24, 2022 after testing negative). On an unknown date, the patient experienced COVID-19 (COVID-19). The patient was treated with NIRMATRELVIR, RITONAVIR (PAXLOVID) from 05-May-2022 to 07-May-2022 for COVID-19 treatment, at an unspecified dose and frequency. At the time of the report, COVID-19 (Tested Positive on May 24, 2022 after testing negative) was resolving and COVID-19 (COVID-19) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 24-May-2022, SARS-CoV-2 test: positive Positive.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Company comment: This spontaneous case concerns a 42-year-old male patient with history of interchange of vaccine products, who experienced the unexpected non-serious AESI of Covid-19, approximately five months after receiving the first dose of mRNA-1273 vaccine. The patient received a course of Paxlovid (Nirmatrelvir + Ritonavir) as a treatment for Covid-19 for five days. Two weeks later he tested positive again after being tested negative prior to this. Details of clinical features, investigation reports and treatment were not provided. The current pandemic situation of Covid-19 could be a confounder. Approximately eight months prior to the Moderna dose, the patient had received one dose of Johnson & Johnson Covid-19 vaccine (Inappropriate schedule of vaccination). The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.; Sender's Comments: This spontaneous case concerns a 42-year-old male patient with history of interchange of vaccine products, who experienced the unexpected non-serious AESI of Covid-19, approximately five months after receiving the first dose of mRNA-1273 vaccine. The patient received a course of Paxlovid (Nirmatrelvir + Ritonavir) as a treatment for Covid-19 for five days. Two weeks later he tested positive again after being tested negative prior to this. Details of clinical features, investigation reports and treatment were not provided. The current pandemic situation of Covid-19 could be a confounder. Approximately eight months prior to the Moderna dose, the patient had received one dose of Johnson & Johnson Covid-19 vaccine (Inappropriate schedule of vaccination). The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.